Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. MDS: Causes

    What causes MDS? Most experts agree that MDS should be considered a cancer of the blood and bone marrow . Often ... treatments. These can cause treatment-related or secondary MDS . Treatment-related MDS is often severe and can be more ...

    Page last updated 02/25/2015 - 11:31am.

  2. Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

    ... aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone marrow disorders. For SAA patients, long ... related donor might promote rapid engraftment and reduce TRM secondary to prolonged neutropenia associated with conventional UCBT. This ...

    Clinical Trial last updated 04/25/2016 - 2:18pm.

  3. Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission (QUAZAR AML-001)

    ... of de novo AML (Acute Myeloid Leukemia) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia ... myelodysplastic syndromes (MDS) Associated Drug(s):  ...

    Clinical Trial last updated 04/29/2016 - 8:39am.

  4. Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)

    ... a UCB transplant can improve response in participants with MDS, leukemia, lymphoma, or MM. The safety of this treatment and whether NK ... of minimal residual disease by flow cytometry ), secondary leukemia from prior chemotherapy and/or arising from MDS, any ...

    Clinical Trial last updated 06/06/2016 - 10:28am.

  5. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... CD123+ acute myeloid leukemia (AML) de novo , or secondary Relapsed AML is defined as patients that had a first ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  6. Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... of minimal residual disease by flow cytometry ), secondary leukemia from prior chemotherapy and/or arising from MDS, ...

    Clinical Trial last updated 06/06/2016 - 12:58pm.

  7. Myelofibrosis (MF)

    ... vera or essential thrombocytosis. This is called secondary myelofibrosis. Patients with MDS, leukemia or even lymphoma can also have fibrosis in their bone ...

    Topic section last updated 07/07/2016 - 3:16pm.

  8. Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

    ... stem cell transplantation in patients with high-risk MDS/AML. We hypothesize that adding valproic acid to azacitidine will improve ... In addition to assessing for 1 year survival, we will have secondary objectives of assessing progression-free survival, relapse, and ...

    Clinical Trial last updated 04/29/2016 - 12:35pm.

  9. Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... t (8;21), t(15;17), inv 16 without c-kit mutations). Secondary AML in remission AML in ≥ 2nd remission ALL in 1st ... t (8;21), t(15;17), inv 16 without c-kit mutations). Secondary AML in remission AML in ≥ 2nd remission ALL in 1st ...

    Clinical Trial last updated 04/29/2016 - 1:11pm.

  10. CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

    ... versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, ... myelodysplastic syndromes (MDS) Gender:  ...

    Clinical Trial last updated 06/13/2016 - 2:06pm.